Protagonist Therapeutics PTGX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $74.06M+61.0% | $46.02M-78.0% | $209.22M0.0% | $209.18M+0.7% | $207.8M-52.2% | ||
| $170.14M+6.8% | $159.29M+7.7% | $147.84M+2.8% | $143.8M+2.5% | $140.29M+1.6% | ||
| $46.39M+3.4% | $44.85M+5.9% | $42.37M+2.3% | $41.4M+2.8% | $40.29M-7.3% | ||
| $216.53M+6.1% | $204.14M+7.3% | $190.21M+2.7% | $185.2M+2.6% | $180.58M-0.6% | ||
| $216.53M+6.1% | $204.14M+7.3% | $190.21M+2.7% | $185.2M+2.6% | $180.58M-0.6% | ||
| -$142.47M+9.9% | -$158.13M-932% | $19.01M-20.7% | $23.98M-11.9% | $27.22M-89.2% | ||
| -192.4%+151pp | -343.6%-353pp | 9.1%-2.4pp | 11.5%-1.6pp | 13.1%-45.1pp | ||
| $27.09M-5.9% | $28.79M-0.3% | $28.88M-2.1% | $29.51M0.0% | $29.51M+12.1% | ||
| —— | —— | $182K-37.2% | $290K-17.4% | $351K+40.4% | ||
| -$115.38M+10.8% | -$129.31M-369% | $48.07M-10.6% | $53.78M-5.8% | $57.09M-79.6% | ||
| -$664K-179% | $838K-61.2% | $2.16M+24.1% | $1.74M+94.9% | $894K-78.8% | ||
| -$114.71M+11.9% | -$130.15M-383% | $45.91M-11.8% | $52.04M-7.4% | $56.19M-79.6% | ||
| -154.9%+128pp | -282.8%-305pp | 21.9%-2.9pp | 24.9%-2.2pp | 27%-36.3pp | ||
| -$1.82+11.7% | -$2.06-417% | $0.65-11.0% | $0.73-6.4% | $0.78-81.6% | ||
| -$1.81+12.1% | -$2.06-368% | $0.77-9.4% | $0.85-5.6% | $0.90-80.0% | ||
| 261.3M+3.0% | 253.8M-0.6% | 255.3M+0.8% | 253.3M+0.9% | 251.1M-0.3% | ||
| 255.9M+0.8% | 253.8M+0.8% | 251.8M+0.8% | 249.8M+0.9% | 247.6M+0.9% | ||
| —— | —— | $182K-37.2% | $290K-17.4% | $351K+40.4% | ||
| -$142.47M+9.9% | -$158.13M-932% | $19.01M-20.7% | $23.98M-11.9% | $27.22M-89.2% | ||
| -$141.02M+10.1% | -$156.85M-883% | $20.03M-19.5% | $24.87M-11.4% | $28.05M-88.9% | ||
| -$141.02M+10.1% | -$156.85M-883% | $20.03M-19.5% | $24.87M-11.4% | $28.05M-88.9% | ||
| -190.4%+150pp | -340.9%-350pp | 9.6%-2.3pp | 11.9%-1.6pp | 13.5%-44.9pp | ||
| -$142.47M+9.9% | -$158.13M-932% | $19.01M-20.7% | $23.98M-11.9% | $27.22M-89.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics (PTGX) generated $74.1M in revenue over the trailing twelve months, down 64.4% year over year.
- Is Protagonist Therapeutics profitable?
- Protagonist Therapeutics is not currently profitable: it reported a net loss of $114.7M over the trailing twelve months, a -154.9% net margin.
- What is Protagonist Therapeutics's earnings per share?
- Protagonist Therapeutics's diluted EPS over the trailing twelve months is $-1.82.
- Where does Protagonist Therapeutics's income statement data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
